UCB SA (Euronext: UCB) is a Belgium-based biopharmaceutical and specialty chemical company  founded on 18 January 1928. The companyt specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology.

In the area of central nervous system disorders, the company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson's disease, and in the area of immunology on allergies, bone loss disorders, Crohn's disease, rheumatoid arthritis and Systemic lupus erythematosus.

UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. UCB also has a selective presence in primary care. The Company, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States.

In 2006, UCB started the purchase of the German pharmaceutical company Schwarz for €4.4 billion[3]. As of July 2007, UCB holds approximately 87% of Schwarz's outstanding shares. The purchase of Schwarz enabled UCB to introduce two new drugs against CNS disorders: Neupro (rotigotine), a transdermal patch for treatment of Parkinson's disease and Vimpat (lacosamide), a new anticonvulsant. Another new drug of the Schwarz portfolio, Toviaz (fesoterodine), a compound to treat overactive bladder, was licensed to Pfizer in 2006.

As of December 31, 2008, UCB SA had a number of wholly owned subsidiaries in the United States, Canada, Europe, Asia, South America and Australia.

Company Website: www.ucb.com
Corporate Responsibility Website: Corporate and Social Responsibility at UCB